Literature DB >> 31509453

A Clinicopathologic and Molecular Update of Pancreatic Neuroendocrine Neoplasms With a Focus on the New World Health Organization Classification.

Jiayun M Fang1, Jiaqi Shi1.   

Abstract

CONTEXT.—: According to the 2017 World Health Organization classification, pancreatic neuroendocrine neoplasms (PanNENs) include a new category of pancreatic neuroendocrine tumor, grade 3, which is often difficult to differentiate from pancreatic neuroendocrine carcinoma. However, pancreatic neuroendocrine tumor grade 3 and pancreatic neuroendocrine carcinoma are distinct entities with very different clinical presentation, prognosis, and therapeutic strategies. Recent discoveries on the molecular characteristics of pancreatic neuroendocrine tumors also play an essential role in the pathologic differential diagnosis of PanNENs. In addition, the histopathologic varieties of PanNENs bring in many differential diagnoses with other pancreatic neoplasms, especially acinar cell carcinoma, solid pseudopapillary neoplasm, and ductal adenocarcinoma. OBJECTIVE.—: To provide a brief update of the World Health Organization classification; the clinical, histopathologic, immunohistochemical, and molecular characteristics; and the differential diagnoses and biological behavior of PanNENs. DATA SOURCES.—: Analysis of the pertinent literature (PubMed) and authors' clinical practice experience based on institutional and consultation materials. CONCLUSIONS.—: The evolving clinical, histopathologic, immunohistochemical, and molecular features of PanNENs are reviewed. Important differential diagnoses with other neoplasms of the pancreas are discussed.

Entities:  

Mesh:

Year:  2019        PMID: 31509453      PMCID: PMC7141760          DOI: 10.5858/arpa.2019-0338-RA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  35 in total

Review 1.  Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances.

Authors:  Julie M Guilmette; Vania Nosé
Journal:  Adv Anat Pathol       Date:  2019-01       Impact factor: 3.875

2.  DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.

Authors:  Yuchen Jiao; Chanjuan Shi; Barish H Edil; Roeland F de Wilde; David S Klimstra; Anirban Maitra; Richard D Schulick; Laura H Tang; Christopher L Wolfgang; Michael A Choti; Victor E Velculescu; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos
Journal:  Science       Date:  2011-01-20       Impact factor: 47.728

3.  Nonductal neoplasms of the pancreas.

Authors:  David S Klimstra
Journal:  Mod Pathol       Date:  2007-02       Impact factor: 7.842

Review 4.  Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management.

Authors:  Jordan M Cloyd; George A Poultsides
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

5.  Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival.

Authors:  T R Halfdanarson; K G Rabe; J Rubin; G M Petersen
Journal:  Ann Oncol       Date:  2008-05-30       Impact factor: 32.976

6.  A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.

Authors:  Laura H Tang; Olca Basturk; Jillian J Sue; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2016-09       Impact factor: 6.394

7.  The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia.

Authors:  Stefano La Rosa; Francesca Franzi; Silvia Marchet; Giovanna Finzi; Moira Clerici; Davide Vigetti; Anna Maria Chiaravalli; Fausto Sessa; Carlo Capella
Journal:  Virchows Arch       Date:  2008-12-09       Impact factor: 4.064

Review 8.  Diagnosis of Pancreatic Neuroendocrine Tumors.

Authors:  Dong Wook Lee; Michelle Kang Kim; Ho Gak Kim
Journal:  Clin Endosc       Date:  2017-11-30

9.  DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.

Authors:  Joo Kyung Park; Woo Hyun Paik; Kyoungbun Lee; Ji Kon Ryu; Sang Hyub Lee; Yong-Tae Kim
Journal:  Oncotarget       Date:  2017-07-25

10.  Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.

Authors:  C G Genç; M Falconi; S Partelli; F Muffatti; S van Eeden; C Doglioni; H J Klümpen; C H J van Eijck; E J M Nieveen van Dijkum
Journal:  Ann Surg Oncol       Date:  2018-05-22       Impact factor: 5.344

View more
  10 in total

1.  Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a radiomic model to predict tumor grade.

Authors:  Giuditta Chiti; Giulia Grazzini; Federica Flammia; Benedetta Matteuzzi; Paolo Tortoli; Silvia Bettarini; Elisa Pasqualini; Vincenza Granata; Simone Busoni; Luca Messserini; Silvia Pradella; Daniela Massi; Vittorio Miele
Journal:  Radiol Med       Date:  2022-08-02       Impact factor: 6.313

2.  Transcriptional Profiling Reveals the Regulatory Role of DNER in Promoting Pancreatic Neuroendocrine Neoplasms.

Authors:  Rui He; Wunai Zhang; Shuo Chen; Yang Liu; Wenbin Yang; Junhui Li
Journal:  Front Genet       Date:  2020-11-27       Impact factor: 4.599

3.  Application of Radiomics Analysis Based on CT Combined With Machine Learning in Diagnostic of Pancreatic Neuroendocrine Tumors Patient's Pathological Grades.

Authors:  Tao Zhang; YueHua Zhang; Xinglong Liu; Hanyue Xu; Chaoyue Chen; Xuan Zhou; Yichun Liu; Xuelei Ma
Journal:  Front Oncol       Date:  2021-02-11       Impact factor: 6.244

Review 4.  Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.

Authors:  Diletta Calabrò; Giulia Argalia; Valentina Ambrosini
Journal:  Diagnostics (Basel)       Date:  2020-12-07

Review 5.  An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Jiayun M Fang; Jay Li; Jiaqi Shi
Journal:  World J Gastroenterol       Date:  2022-03-14       Impact factor: 5.374

6.  Reappraisal of a 2-cm Cutoff Size for the Management of Nonfunctional Pancreatic Neuroendocrine Tumors: A Population-Based Study.

Authors:  Zhen Yang; Dongsheng Zhang; Guangjun Shi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-18       Impact factor: 6.055

7.  Clinical Data-CT Radiomics-Based Model for Predicting Prognosis of Patients with Gastrointestinal Pancreatic Neuroendocrine Neoplasms (GP-NENs).

Authors:  Peng An; Junyan Zhang; Mingqun Li; Peng Duan; Zhibing He; Zhongq Wang; Guoyan Feng; Hongyan Guo; Xiumei Li; Ping Qin
Journal:  Comput Math Methods Med       Date:  2022-08-05       Impact factor: 2.809

Review 8.  Intraductal tubulopapillary neoplasm (ITPN) of the pancreas: a distinct entity among pancreatic tumors.

Authors:  Gaetano Paolino; Irene Esposito; Seung-Mo Hong; Olca Basturk; Paola Mattiolo; Takuma Kaneko; Nicola Veronese; Aldo Scarpa; Volkan Adsay; Claudio Luchini
Journal:  Histopathology       Date:  2022-05-27       Impact factor: 7.778

9.  Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast.

Authors:  Gregory R Bean; Saleh Najjar; Sandra J Shin; Elizabeth M Hosfield; Jennifer L Caswell-Jin; Anatoly Urisman; Kirk D Jones; Yunn-Yi Chen; Gregor Krings
Journal:  Mod Pathol       Date:  2022-05-19       Impact factor: 8.209

10.  Reconsideration of Clinicopathologic Prognostic Factors in Pancreatic Neuroendocrine Tumors for Better Determination of Adverse Prognosis.

Authors:  Anil Aysal; Cihan Agalar; Tufan Egeli; Tarkan Unek; Ilhan Oztop; Funda Obuz; Ozgul Sagol
Journal:  Endocr Pathol       Date:  2021-07-20       Impact factor: 3.943

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.